Background: Haematopoietic stem cell transplantation (HSCT) for patients with severe combined immunodeficiency (SCID) can be highly effective. However, in a few patients long term immune function is poor with abnormalities in humoral and/or cell mediated immunity. Aims: To test if a late CD34+ stem cell 'top up' +/-donor lymphocyte infusion (DLI) from the original donor may allow restoration of immune function. Methods: 3 post transplant SCID patients with poor immune function as defined by immunological and clinical parameters were given CD34+ stem cells from their original donors (mean duration since primary SCT: 16.5 years). Patient 1 subsequently received 2 donor lymphocyte infusions. Conditioning was not used. Mean follow up time 15 months. Results:
Conclusions: The clinical impact of poor immune function many years after HSCT for SCID is increasing being recognised. This initial study suggests that stem cell 'top ups' are safe and not associated with any toxicity. This procedure may allow improvement of immunological and clinical parameters.
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Pulmonary function in children with beta-thalassemia before and after bone marrow transplantation -a single center study H.A. El-Faraidi, L.M. Ball, T. J. Hilterman, F.J. Smiers, A.C. Lankester, R.G. Bredius, D. Bresters, J.D. Bakker, J.M. Vossen, R.M. Egeler (Leiden, NL) Lung function abnormalities have been described in children with homozygous beta-thalassemia undergoing transfusion/chelation programmes. A restrictive defect seems most common and may be related to serum ferritin although the pathogenesis is unclear. Allogeneic bone marrow transplantation (BMT) is a curative option for thalassemia. The extent of this phenomenon in children undergoing SCT is unknown, as is the relationship to iron stores as documented by routine pre-transplant liver biopsy. We retrospectively analyzed data in children undergoing BMT to determine the role of iron overload in the pathogenesis of pulmonary changes as determined by lung function tests (LFTs). All patients successfully undergoing HLA-identical BMT for bthalassemia between 1984 -2002 were retrospectively reviewed. Standard LFTs were carried out and included FEV, FEV1, TLC and diffusion capacity. Bone marrow trephine biopsies were examined for iron deposition and liver biopsies histologically graded1. Serum ferritin was measured pre and sequentially post BMT.
Evaluable data was available in 11/14 children. Results and patient characteristics are summarized in Table 1 . One patient also had the results of a lung biopsy +4 months post-transplant. All patients had normal chest X-ray and cardiac evaluation. No patients had documented BOOP or clinically evident pulmonary GvHD. In our patient group only four children had mild abnormalities pre-transplant. Post-transplant, however, mild-to moderate restrictive lung patterns with reduced diffusion capacity developed in five additional patients. All these abnormalities improved on long term follow-up (at +1 year). There was no correlation with the degree of iron overload, risk category or GvHD. In children undergoing BMT for thalassemia, established lung dysfunction, irrespective of iron status, is not clinically relevant. However, post-BMT restrictive LFTs may reflect either toxicity or sub-clinical GvHD, both of which may be exacerbated by the pulmonary iron deposition. 1 Angelucci E, Baronciani D, Lucarelli G, et al. Br J Haematol 1995; 89:757-61. 2 Lucarelli G, Galimberti M, Polchi P, et al. Blood 1992; 80:1603-09 .
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Non-myeloablative stem cell transplantation in adrenoleukodystrophy J. Kapelushnik, Y. Shapira, M. Aker, E. Hershkoviz, A. Moser, S. Selavin, R. Or (Beer Sheva, Jerusalem, IL) X-linked ALD is a progressive disorder effecting myelin, caused by a defect in the adenosine triphosphate gene (ATP -binding cassette subfamily D). Stem cell transplantation (SCT), if performed when brain involvement is mild, can provide long-term benefits. Experience using non-myeloblative SCT in the treatment of ALD is limited. Here we present the three ALD patients, aged 7, 8 and 9.5 years, treated with non-myeloblative SCT. Two children displayed hyperactive behavior, without neurological deficit, before transplantation. Abnormal MRI scans revealed diffuse white matter involvement in all three cases. Psychological assessments using the Whechler intelligence scale, were in the low normal range for all patients. The conditioning regimen for SCT consisted of ATG 5mg/Kg for 4 days, busulfan 3.2mg/Kg for 4 days and Fludarabine 30 mg/Kg for six days. Cyclosporin-A and a short course of MTX were used prophylactically against GVHD. Rapid engraftment was noted with more then 1000 ANC at day 4, 14, and 15 post SCT. Two patients had fever and were treated with antibiotics. Full chimerism of donor origin was noted 6 months post SCT. No significant changes in very long fatty acid levels, from pretransplantation to follow up, were found in any of the patients. Patient follow up at 9, 12, and 24 months post SCT did not show neurological deterioration.
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Allogeneic hematopoietic stem cell transplantation for children with severe combined immunodeficiency I. Tezcan, T. Turul, D. Uckan, M. Cetin, H. Cüzdancý, Ö. Sanal, F. Ersoy (Ankara, TR) Since 1995, 31 hematopoietic stem cell transplantations were performed for 29 children with severe combined immunodeficiency (SCID). Fourteen donors were HLA-identical or one antigen mismatch siblings, 9 donors were HLA-identical or one antigen mismatch parents and 6 were haploidentical parents. Eleven patients were T -B-NK+, 7 patients were T -B+NK-, 7 patients were T-B+NK+ and 4 patients were diagnosed as combined immunodeficiency, one of which was shown to have JAK3 deficiency with maternal engraftment. Haploidentical transplantations were performed as peripheral blood stem cell infusion after CD34+ positive selection. The patients' ages were ranging between 1.5 and 24 months with a median of 8.5 months. Twenty out of 29 (%68.9) patients are well and alive with a follow up period of +3 months -+8 years (median 24 months). Out of 9 patients who died, four were T-B-NK+, 2 were T-B+NK+ and 3 patients were diagnosed as combined immunodeficiency. However there was no mortality in the T-B+NK-group. Main cause of mortality was lung infection (n:7) acquired either in the pre or immediate posttransplant period as a result of delayed diagnosis and followed by pulmonary hemorrhage (n:1) and neurologic complications (n:1). Acute graft versus host disease (GVHD) grade 2 developed in 3 patients receiving peripheral blood stem cell transplantation(PSCT)while in 3 patients limited chronic GVHD was diagnosed, in one as continuation of acute GVHD. Disseminated BCG infection was observed in 5 patients. Since the major cause of mortality was interstitial pneumonia especially existing before transplantation in this cohort, effort for earlier diagnosis should be the essential priority especially in our country.
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Comparison of the mesenchymal stem cells and stromal cell layers derived from bone marrow of patients with osteogenesis imperfecta and healthy controls I.C.M. Slaper-Cortenbach, K. Sijssens, A. van Royen, M. Wassen, H. Pruijs, R.J.B. Sakkers, N.M. Wulffraat (Utrecht, NL) Patients with Osteogenesis Imperfecta (O.I) have a genetic disorder, which affects the collagen type I formation in bone and soft tissues. Horwitz et al (Blood 2001) have shown that transplantation of allogeneic bone marrow stem cells can improve the clinical outcome for children with severe OI. The addition of donor-derived cultured Mesenchymal Stromal Cells (MSC) might also contribute to a reduction of abnormal bone formation. Aim of this study was to compare the number of MSC measured in bone marrow from children with O.I and normal controls using the CFU-F assay. Furthermore, stromal cell cultures were set up and osteoblast differentiation was induced using Vitamin C, Dexamethason and ß-glycerophosphate. Bone marrow cells were harvested during orthopedic surgery from femur, cristae and tibia and separated over a Ficoll density gradient. No differences were measured in the recovery of the number of nucleated cells (OI: 23.5% ± 16 (n=15), control: 27.5% ± 9.9 (n = 15)). Detection of the number of CFU-F however, could only be measured in 4 out of 12 control bone marrow cells and in 2 out of 2 bone marrow cells from patients with O.I. This might indicate a higher turn over in the MSC compartment. In the stromal cell cultures, the proliferation of MSC did not differ. The adherent cell population and consecutive passages (up to P3) did not result in different cell numbers nor was there a difference in the mean number of days to reach 80% confluence. At P3, the stromal cell populations consisted of CD 105+/CD34-/CD31-/CD14-cells that were only partly positive for the fibroblast marker TE-7. Osteoblast differentiation was equally detected in both groups and is subject of further studies in patients with a variety of osseous defects and immunodeficiencies, such as cartilage hair syndrome, osteopetrosis and OI. For these diseases, stem cell transplantation protocols will be proposed in addition to in vitro amplification of donor MSC.
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Transplantation of bone marrow as compared with peripheral blood stem cell from HLA-identical siblings in patients with thalessemia major in Iran A. Ghavamzadeh, B. Bahar, M. Iravani, M. Jahani, A. Mousavi, K. Alimoghaddam, S. Gholibeikian, L. Eghbal, F. Safavifar (Tehran, IR) Objectives: To compare bone marrow and peripheral blood stem cell transplantation in thalassemia major patients in our center. Methods: We studied engraftment kinetics, incidence of graftversus-host disease (GVHD) and outcome of allogeneic PBSCT vs. BMT in 180 Beta Thalassemia Major Patients in our center between 1991 to November 2002. Patients' mean age was 6 years (2.5-17years).Classification of their disease was class 1=66, Class 2=70, Class 3=44. 147 out of 180 have passed at least 100 days after transplantation. Conditioning regimens in class 1and 2 were Cyclophosphamide 50 mg/kg for 4 days + Busulfan 3.5 mg/kg for 4 days and in class 3, Cyclophosphamide 40 mg/kg for 4 days + Busulfan 4 mg/ kg for 4 days. We used Cyclosporin 3 mg/kg (IV) from day -2 to +5 and then 12.5 mg/kg (PO) from day +6 plus Methotraxate 10 mg/m2 in day +1 and then 6 mg/m2 on days +3,+6 as GVHD prophylaxis regimen. Results: Myeloid and platelet engraftment (PMN >0.5x10^9/L and PLT> 20 x 10^9/L) occurred at median 18.8 and 21.2 days after PBSCT Vs. 26.2 and 34.2 days after BMT respectively (PValue=0.02).Incidence of severe aGVHD were similar in both groups (21% grade 3-4 in PBSCT vs. 20% in BMT). Chronic GVHD occurrence in 147 patients was 37.8% (Limited 25% and Extensive 12.8%),from which 58.4% was in PBSCT (Limited 33.9%, Extensive 24.5%) versus 41.5% in BMT (Limited 32%, Extensive 9.5%). Mortality rate of cGVHD was 5.6% occurring only in PBSCT. Hospitalization was the same in both groups (mean 44 days).Overall survival (5-10 years) was 80% and thalassemia free survival (5-10 years), 71% .There were no significant differences between the two groups. Conclusion: Engraftment in PBSCT was faster than BMT without subsequent differences in aGVHD, but occurrence of cGVHD (Limited and Extensive) in PBSCT was more than BMT.
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Stem cell transplantation in hemoglobinopathies -the Turkish experience
M.A. Yesilipek, S. Kansoy, A. Tanyeli, M. Ertem, M. Cetin, G. Gedikoglu, V. Hazar, E. Kürekci on behalf of the Turkish Pediatric Group
Stem cell transplantation (SCT) is considered as the only curative treatment approach for haemoglobinopathies. Successful cure of beta thalassemia by bone marrow transplantation was first reported by Thomas and associates in 1982. Subsequently, a number of centers have explored this method as a curative therapy for beta thalassemia. Here, we report the Turkish pediatric group experience of 83 stem cell transplantation in 71 patients with haemoglobinotathies. Sixtyeight of the patients were homozygous beta thalassemia, two were homozygous HbS and one was HbS-Beta thalassemia. F/M ratio was 39 / 32 and median age of the patients was 5 years (9 mos to15 yrs). Twenty-five of them were Class I, 28 patients were Class II and 25 patients were Class III according to Pesaro criteria. All of the patients were transfusion dependent. Stem cell sources were bone marrow, peripheral blood, and cord blood in 51, 28, and 3 transplantation respectively. Bone marrow plus cord blood were used in one patient. All donors were HLAidentical, 64 were siblings and 7 were parents. Conditioning regimens consisted of BU+CY (60 patients) , BU+CY+ATG (15 patients), BU + Thiotepa + CY (4 patients), TLI+ATG (1 patient), ATG (1 patient) and Pesaro Protocol 26 in 2 patients . All patients received CsA and /or MTX or prednisolon for GVHD prophylaxis. Engraftment was achieved in all patients. Median neutrophile engraftment time was 15 days and platelet engraftment time was 24 days. We observed acute GVHD in 16 patients (22.53%) and chronic GVHD in 3 patients. Graft rejection was seen in a total of 19 transplants (5 to 18 mos after SCT), 16 with recurrence of thalassemia and 3 with aplasia. Second SCT was performed in 12 patients. Median age was 8 y and eight of them Class II and four patients were Class III. Median interval between rejection and second transplantation was 12 months in second transplantation group. Sources of stem cell were BM in eight and peripheral blood in four patients. Six patients cured in this group. Of the 13 patients who died (18.3%), causes of death were infection in 8 , hemorrhage in 3 patients, VOD in one a nd interstitial pneumonia in one patient. In our series; event free survival was found as 62% and overall survival 81.70%. We conclude that stem cell transplantation is the only curative treatment method for thalassemic children who have HLA-identical siblings or parents.
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Favorable outcome of stem cell transplantation in severe thalassemia with alternative donors: matched unrelated and haploidentical donors S. Hongeng, S. Pakakasama, A. Chuansumrit, N. Sirachainunt, P. Tardtong, P. Kraiphibul, S. Jootar (Bangkok, TH) Allogeneic BMT from HLA-identical family donors is the onyl curative procedure for thalassemia (thal). However, only 30% of these patients can have matched sibling donors available. Recent data reported that event free survival of matched unrelated donor (MUD) transplant in thalassemia was 69% (n=32). Between March 2001 and November 2002, 12 thalassemia patients (pts) were included in this study. Eight were male; 4 female. Age ranged between 2 yrs and 18 yrs (median; 7yrs). Six had beta thal major and six had beta thal/HbE. Eleven received MUD transplant and one received haploidentical transplant (CD34+ purification method). The conditioning regimen of MUD transplant consisted of busulfan (16mg/kg), cyclophosphamide (200mg/kg), and ATG (Fresinius) 60mg/kg. The conditioning of haploidentical transplant consisted of busulfan (8mg/kg), thiotepa (5mg/kg), fludarabine (200mg/m2), ATG(25mg/kg), and TLI 500cGy). GVHD prophylaxis was with cyclosporin and mycophenolate mofetil (MMF)in 7 pts, FK506 and MTX in 3 pts, and FK506 and MMF in 2 pts. Neutrophil engraftment was achieved at day +14, platelet engraftment was achieved at day+ 60. Eight pts had acute GVHD grI-II and none had acute GVHD grIII-IV. One had chronic GVHD (limited). All pts (100%) survived without disease with median follow up time 1yr. Chimerism study demonstrated full donor chimerism (100%) in all pts.
Oral Session: Aplastic anemia
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The type of graft-versus-host disease prophylaxis influences the degree of hematopoietic chimeraism following allogeneic bone marrow transplantation for severe aplastic anaemia -a comparison between cyclosporine and cyclosporine and methotrexate S. McCann, M. Lawler, F. Locatelli, A. Locasciulli, B. Bruno, J. Passweg, H. Schrezenmeier Locatelli et all demonstrated a survival advantage for patients with severe aplastic anaemia receiving a sibling allograft who received cyclosporine(Csa) and methotrexate (Mtx) over cyclosporine alone as prophylaxis against Graft versus Host Disease (GvHD). This study was undertaken on a sub group to determine if the type of GvHD prophylaxis influenced the degree of haemopoietic chimaerism. Forty seven patients who received bone marrow from sibling donors and survived > 14 days were studied on at least three occasions (3-15) following transplant. Twenty two received Csa and 25 Csa and Mtx. Peripheral blood or bone marrow slides were evaluated for informative polymorphisms using PCR of short tandem repeats. Informative polymorphisms were detected in all pairs and results were interpreted without knowledge of the type of prophylaxis given. Patients were followed 44-130 months after transplant. Four groups were identified, complete donor chimeras, transient mixed chimeras, stable mixed chimaeras and progressive mixed chimeras. Six (13%) patients had graft failure, 3 prior to day 20 and three subsequently. Three are alive, 2 with autologous recovery and one had a second transplant. The cell dose given was critical in determining the probability of graft failure. MNC of 1.1-3.3 x 108/kg was associated with a probability of 0.33 whereas the probability with a cell dose >5.6 was 0.001. Csa and Mtx were associated with a higher incidence of donor and transient mixed chimaerism (p<0.05) and patients receiving the two drugs experienced more chronic GvHD (p<0.05). There was no difference in the incidence of progressive mixed chimaerism in either group. Patients who were stable mixed chimaeras never experienced chronic GvHD irrespective of the prophylaxis. We conclude that a combination of Csa and Mtx is associated with an increased rate of complete donor chimerism and a higher incidence of cGvHD following BMT for SAA. Locatelli F et al. Blood 1,2000 : 1690 -1697 .
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Long-term survival after transplantation for aplastic anemia: impact of previous treatment and of conditioning regimen L. Adès, J.-Y. Mary, M. Robin, A. Devergie, P. Ribaud, H. Esperou, E. Gluckman, G. Socié (Paris, F) This study included 133 patients (pts) who underwent allogeneic bone marrow transplantation (BMT) from an HLA identical sibling, after TAI-Cy (n=100) and Cy-ATG (n=33), respectively. Median follow-up was 12.6 years. There was 80 men and 53 women, median age was 19 years (4-46), 75 met criteria for SAA at diagnosis, 67 were first treated by immunosuppressive therapy +/-androgens before transplant. Median time from diagnosis to BMT was 300d (10d 10y); and 48 pts received more than 20 transfusions before BMT. Acute GvHD prophylaxis consisted in methotrexate (n=14), cyclosporine (n=44), cyclosporine and methotrexate (n=70), others (n=5). Bone marrow failure or rejection occurred in 9 patient. Both grade II-IV acute GvHD (42% vs. 0%, p<0.001) and chronic GvHD (5-year incidence 70% vs. 49%, p=.01) rates were increased following TAI. Avascular necrosis 5-year cumulative probability was 28% and 14% after Cy-ATG & Cy-TAI, respectively (p=0.05) . 10 solid tumors were diagnosed, 8 after TAI-Cy, 2 after ATG-Cy, leading to an overall
